tiprankstipranks
Trending News
More News >
Utah Medical Products (UTMD)
:UTMD
Advertisement

Utah Medical Products (UTMD) AI Stock Analysis

Compare
120 Followers

Top Page

UTMD

Utah Medical Products

(NASDAQ:UTMD)

Rating:77Outperform
Price Target:
$65.00
▲(4.48% Upside)
Utah Medical Products scores well due to its strong financial performance, characterized by robust profitability and a healthy balance sheet. Technical analysis supports a neutral to slightly positive outlook, while valuation metrics suggest the stock is fairly valued with a reasonable dividend yield. The absence of earnings call data and corporate events does not impact the score.

Utah Medical Products (UTMD) vs. SPDR S&P 500 ETF (SPY)

Utah Medical Products Business Overview & Revenue Model

Company DescriptionUtah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
How the Company Makes MoneyUTMD generates revenue primarily through the sale of its medical devices, which are distributed to hospitals, clinics, and healthcare providers both domestically and internationally. The company's revenue model is based on the direct sales of its proprietary products, which are often sold under long-term contracts or as part of bulk orders. Key revenue streams include sales from its obstetric and urological product lines, as well as ongoing revenue from consumables and accessories related to these devices. Additionally, UTMD benefits from strategic partnerships with medical distributors and healthcare organizations, which enhance its market reach and contribute to consistent sales growth. The company also invests in research and development to innovate and expand its product offerings, thereby driving future revenue potential.

Utah Medical Products Financial Statement Overview

Summary
Utah Medical Products displays a robust financial position with strong profitability, minimal leverage, and efficient cash flow management. Despite a decline in revenue and operating cash flow in the TTM, the company maintains solid margins and a healthy balance sheet, supporting its stability and growth potential in the medical instruments sector.
Income Statement
78
Positive
The income statement reveals a declining revenue trend over the years, with a revenue decrease from $52.28M in 2022 to $39.27M in the TTM. However, the company maintains strong profitability with a consistent gross profit margin and a solid net profit margin of approximately 33% in the TTM. The EBIT and EBITDA margins are robust, reflecting efficient cost management.
Balance Sheet
85
Very Positive
The balance sheet is strong, with a very low debt-to-equity ratio indicating minimal leverage, enhancing financial stability. The equity ratio is high, showcasing a strong capital structure with stockholders' equity making up a significant portion of total assets. However, a slight decrease in stockholders' equity is noted in the TTM.
Cash Flow
82
Very Positive
The cash flow statement shows healthy free cash flow generation with minimal capital expenditures. The operating cash flow to net income ratio is strong, indicating efficient cash conversion. However, there is a decline in operating cash flow from $21.23M in 2022 to $14.02M in the TTM, which may need attention.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue40.90M50.22M52.28M49.05M42.18M
Gross Profit24.14M30.04M32.20M30.92M25.55M
EBITDA16.44M24.75M26.87M26.16M20.92M
Net Income13.87M16.64M16.47M14.79M10.80M
Balance Sheet
Total Assets122.54M135.46M123.87M115.56M111.75M
Cash, Cash Equivalents and Short-Term Investments82.98M92.87M75.05M60.97M51.59M
Total Debt282.00K295.00K341.00K396.00K335.00K
Total Liabilities5.11M7.14M9.62M8.42M8.92M
Stockholders Equity117.43M128.31M114.25M107.14M102.82M
Cash Flow
Free Cash Flow14.60M21.64M20.33M20.65M19.28M
Operating Cash Flow14.83M22.28M21.15M21.20M20.14M
Investing Cash Flow-208.00K-639.00K-818.00K-552.00K-860.00K
Financing Cash Flow-23.84M-4.17M-5.48M-10.90M-10.73M

Utah Medical Products Technical Analysis

Technical Analysis Sentiment
Positive
Last Price62.21
Price Trends
50DMA
57.28
Positive
100DMA
55.55
Positive
200DMA
57.99
Positive
Market Momentum
MACD
1.33
Negative
RSI
65.93
Neutral
STOCH
92.85
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Positive. The current price of 62.21 is above the 20-day moving average (MA) of 58.29, above the 50-day MA of 57.28, and above the 200-day MA of 57.99, indicating a bullish trend. The MACD of 1.33 indicates Negative momentum. The RSI at 65.93 is Neutral, neither overbought nor oversold. The STOCH value of 92.85 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTMD.

Utah Medical Products Risk Analysis

Utah Medical Products disclosed 9 risk factors in its most recent earnings report. Utah Medical Products reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Utah Medical Products Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$199.43M16.6410.39%1.95%-16.64%-13.64%
75
Outperform
$152.88M16.7528.29%29.65%131.78%
70
Outperform
$220.19M45.459.39%8.13%1293.06%
66
Neutral
$261.08M-198.62%33.94%-6.91%
58
Neutral
$299.65M-25.78%34.29%-49.21%
57
Neutral
$242.08M25.27-12.65%-49.35%-285.61%
51
Neutral
$7.84B-0.18-41.53%2.28%22.72%-1.87%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
UTMD
Utah Medical Products
62.21
-3.21
-4.91%
INFU
InfuSystem Holdings
10.78
4.45
70.30%
OSUR
Orasure Technologies
3.31
-1.06
-24.26%
PDEX
Pro-Dex
46.88
24.55
109.94%
STXS
Stereotaxis
2.88
0.64
28.57%
SMTI
Sanara MedTech
33.66
-0.82
-2.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 19, 2025